Related Experiment Video

Updated: Nov 19, 2025

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.8K

Heartech® left ventricular partitioning device improves left ventricular systolic function of patients with chronic

Xiuxiu Su1, Wenbo Yang1, Zhengbin Zhu1

  • 1Department of Vascular and Cardiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions
|January 27, 2021
PubMed

Insights

The Heartech® left ventricular (LV) partitioning device (LVPD) shows sustained safety and efficacy in heart failure patients one year post-implantation. Echocardiographic outcomes reveal significant improvements in LV systolic function without deterioration in diastolic or right ventricular function.

Area of Science:

  • Cardiology
  • Medical Devices
  • Heart Failure Research

Background:

  • The Heartech® left ventricular (LV) partitioning device (LVPD) demonstrated initial safety and efficacy in a first-in-man study for chronic heart failure (HF) patients post-myocardial infarction (MI) at one month.
  • This study extends the follow-up to one year to assess long-term echocardiographic outcomes in these patients.

Purpose of the Study:

  • To evaluate the 1-year echocardiographic outcomes in patients treated with the Heartech® LVPD for heart failure post-myocardial infarction.
  • To assess the device's impact on left ventricular (LV) systolic and diastolic function, and right ventricular function over a 1-year period.

Main Methods:

  • Fifteen patients with HF post-MI received the Heartech® LVPD via percutaneous ventricular restoration.
  • Echocardiographic parameters, including LV systolic and diastolic function, speckle-tracking analysis, and right ventricular function, were measured pre-implantation, at 1 month, and at 1 year post-implantation.

Main Results:

  • Significant improvement in LV ejection fraction (42.5% to 32.47%; p=0.001) was observed at 1 year compared to pre-procedure.
  • Significant reduction in LV end-diastolic volume index (106.29 to 83.30; p=0.005) and end-systolic volume index (72.47 to 50.00; p=0.001) was noted.
  • No deterioration in LV diastolic function, specific strain parameters, or right ventricular function was observed at 1 year.

Conclusions:

  • The Heartech® LVPD provides sustained benefits for patients with heart failure post-myocardial infarction at the 1-year follow-up.
  • The device significantly improves left ventricular systolic function without compromising diastolic or right ventricular function, confirming its long-term efficacy.
Abstract

Keywords:
echocardiographyheart failureleft ventricular partitioning devicemyocardial infarctionpercutaneous ventricular restoration

More Related Videos

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.7K
Transthoracic Echocardiography to Assess Post-Resuscitation Left Ventricular Dysfunction After Acute Myocardial Infarction and Cardiac Arrest in Pigs08:19

Transthoracic Echocardiography to Assess Post-Resuscitation Left Ventricular Dysfunction After Acute Myocardial Infarction and Cardiac Arrest in Pigs

Published on: July 12, 2022

3.1K

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
124
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
224
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
148
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
151
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
108
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
91